특집/당뇨병 관리의 일반적 원칙 = General Principles for Diabetes Mellitus Management

다국어 초록 (Multilingual Abstract)

Because the ‘Tsunami of type 2 diabetes’ is presently rolling on a global scale, owing to the

ever-increasing prevalence of obesity, increasing physical inactivity, and aging populations

worldwide, the economic burden of diabetes caused by increased health resource use and lost

productivity increase rapidly. So prevention in general population and good glycemic controls become

even more important with earlier diagnosis and more aggressive cardiovascular prevention

and treatment. Diabetes requires continuing medical care and patient self-management education

to prevent acute complications and to reduce the risk of long-term complications. Diabetes care

is very complex and requires that many issues, beyond glycemic control, be solved by the active

governmental policy. Lifestyle modifications are the cornerstones of management of type 2

diabetes. The progressive nature of type 2 diabetes requires use of one or more oral agents and

eventually insulin, along with lifestyle modification and intensification. Rapid achievement of

the target goals often prompts providers to consider combination therapy to target different

pathogenic mechanisms and manage both fasting and postprandial blood glucose levels.

Maintenance of glycemic control over the lifespan of a patient with diabetes is overwhelmingly

likely to require combination therapy with oral diabetes medications. Ultimately, because of the

progressive nature of the disease and the progressive decline in pancreatic beta-cell function,

insulin therapy is almost always obligatory to achieve optimal glycemic goals.

참고문헌 (Reference)

• 1 Torgerson JS, "XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients" 27 : 155-161, 2004
• 2 Roberts VL, "Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebocontrolled, parallel-group study" 27 : 1535-1547, 2005
• 3 Bell DS, "Triple oral therapy for type 2 diabetes" 78 : 313-315, 2007
• 4 Taskforce Team for treatment guideline for diabetes, "Treatment Guideline for Diabetes 1st ed"
• 5 Taskforce Team for treatment guideline for diabetes, "Treatment Guideline for Diabetes 1st ed"
• 6 Chetty VT, "The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger - stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in Type I diabetic patients: a systematic review" 81 : 79-87, 2008
• 7 "Taskforce Team for treatment guideline for diabetes. Treatment Guideline for Diabetes"
• 8 American Diabetes Association, "Standards of Medical Care in Diabetes -2008" 31 : S12-S54, 2008
• 9 Towfigh A, "Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis" 14 : 468-475, 2008
• 10 Welschen LM, "Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review" 28 : 1510-1517, 2005
• 11 UK Prospective Diabetes Study Group, "Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients (UKPDS 7)" 39 : 905-912, 1990
• 12 Korean Diabetes Association, Health Insurance Review & Assessment Service, "Report of Task Force Team for Diabetes Basic Statistics Study Group: Diabetes in Korea 2007" 2007
• 13 Tuomilehto J, "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance" 344 : 1343-1350, 2001
• 14 Kosaka K, "Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males" 67 : 152-162, 2005
• 15 Nathan DM, "Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes" 31 : 173-175, 2008
• 16 Nathan DM, "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes" 353 : 2643-2653, 2005
• 17 ADVANCE Collaborative Group, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes" 358 : 2560-2572, 2008
• 18 Garg S, "Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial" 29 : 44-50, 2006
• 19 Action to Control Cardiovascular Risk in Diabetes Study Group, "Friedewald WTEffects of intensive glucose lowering in type 2 diabetes" 358 : 2545-2559, 2008
• 20 Pan XR, "Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study" 20 : 537-544, 1997
• 21 DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, "Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial" 368 : 1096-1105, 2006
• 22 Knowler WC, "Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin" 346 : 393-403, 2002
• 23 Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study" 321 : 405-412, 2000
• 24 Research Institute for Healthcare Policy Korean Medical Association, "Analysis of the OECD Health Data 2006"
• 25 Chiasson JL, "Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOPNIDDM trial" 290 : 486-494, 2003
• 26 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial, "ACCORD Blood Sugar Treatment Strategy Announcement"